题 目: Overcoming cancer cell drug resistance by targeting P-glycoprotein in the lysosome: The development of novel di-2-pyridylketone thiosemicarbazones
报告人: Des R. Richardson 教授，悉尼大学
时 间: 2018年4月19日（星期四）15:00-16:00
地 点: 中山大学东校园药学院112会议室
Professor Des Richardson holds the Chair of Cancer Cell Biology at the University of Sydney, Australia, and is a National Health and Medical Research Council (NHMRC) of Australia Senior Principal Research Fellow.
He has published > 406 articles, reviews, patents, chapters etc., over his career with >93% as first, senior or corresponding author (H-index: 80; >25,060 citations over entire career; with >14,523 citations over the past 5 years and H-index: 57 over past 5 years).
He is Executive Editor of BBA-General Subjects and has served on the Editorial Boards of >40 international journals, including J. Biol. Chem., Antioxidants Redox Signaling, Biochem. J., BBA-Mol Cell Res, Mol. Pharmacol., Pharmacol. Res., etc.
As a major translational research achievement, he has developed the anti-cancer and anti-metastatic drug, DpC, which overcomes P-glycoprotein mediated drug resistance. This has led to commercialisation of DpC and the development of the international company, Oncochel Therapeutics LLC, USA and its Australian subsidiary, Oncochel Therapeutics Pty Ltd. Notably, DpC has entered multi-centre Phase I clinical trials for the treatment of advanced and resistant cancer. These anti-cancer drugs target the lysosome via the P-glycoprotein transporter.